FDA will issue formal guidance requiring cardiac screening protocols as a precondition for ibogaine IND approval by Q1 2027.

The FDA (the US drug regulator) will publish official written guidance saying that anyone testing ibogaine—a plant-based psychedelic being studied for addiction—must first get heart tests to check for dangerous electrical abnormalities. This matters because ibogaine can affect your heart rhythm, and the FDA needs to protect patients in clinical trials.

Multiple independent cardiac risk publications create an evidentiary record FDA cannot ignore without institutional liability. Formal guidance codifying QT prolongation screening as an IND precondition is a plausible regulatory response. However, FDA guidance timelines are notoriously slow—formal guidance by Q1 2027 (~22 months out) is optimistic. FDA more commonly issues draft guidance first, and the process can take years. Confidence trimmed to reflect procedural drag.